| Title |
A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial
|
|---|---|
| Published in |
Respiratory Research, April 2018
|
| DOI | 10.1186/s12931-018-0751-x |
| Pubmed ID | |
| Authors |
Timm Greulich, Jens M. Hohlfeld, Petra Neuser, Katrin Lueer, Andreas Klemmer, Carmen Schade-Brittinger, Susanne Harnisch, Holger Garn, Harald Renz, Ursula Homburg, Jonas Renz, Anne Kirsten, Frauke Pedersen, Meike Müller, Claus F. Vogelmeier, Henrik Watz |
| Abstract |
A subset of COPD-patients presents with eosinophilic airway inflammation. While treatment of asthmatic patients with the GATA3-specific DNAzyme SB010 attenuated sputum eosinophilia after allergen challenge, this specific treatment has not been evaluated in patients with COPD. Our objective was to evaluate the feasibility and safety of inhaled SB010 in COPD patients with sputum eosinophilia. We conducted a randomized, double-blind, placebo-controlled, multicentre clinical trial in COPD-patients with sputum eosinophilia (≥2.5% non-squamous cells). Patients inhaled 10 mg SB010 bid or matching placebo via the controlled inhalation system AKITA2 APIXNEB for 28 days. Endpoints included the feasibility of the study (primary), patient's safety, sputum eosinophils, FENO, lung function, symptoms, and biomarkers. The study was registered in the German Clinical Trials Register: DRKS00006087. One hundred thirty patients were screened, 23 patients were randomized (FEV1 49.4 ± 11.5%; sputum eosinophils 8.0 ± 8.4%) and 19 patients completed the study (10 placebo, 9 SB010. After 28 days, SB010 decreased the relative sputum eosinophil count (p = 0.004) as compared to no changes in placebo-treated patients. FENO, lung function, and symptoms were not affected significantly. We found an increase in blood IFN-γ (p = 0.02) and a trend to lower IL-5 levels in patients treated with SB010. SB010 was safe and well tolerated. Thirty five AEs (22 SB010, 13 placebo including 1 SAE) were observed with 3 AEs in each group judged to be possibly treatment-related. In patients with eosinophilic COPD, sputum eosinophils could be reduced by inhalation of SB010. Long-term studies are needed to demonstrate clinical efficacy. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 61 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 13% |
| Researcher | 8 | 13% |
| Student > Ph. D. Student | 6 | 10% |
| Other | 4 | 7% |
| Student > Doctoral Student | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 26 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Immunology and Microbiology | 2 | 3% |
| Other | 8 | 13% |
| Unknown | 25 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2021.
All research outputs
#3,344,645
of 25,382,440 outputs
Outputs from Respiratory Research
#423
of 3,062 outputs
Outputs of similar age
#66,070
of 342,873 outputs
Outputs of similar age from Respiratory Research
#13
of 64 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,062 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,873 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.